tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Caufield, 97 are a BUY (85.84%), 16 are a HOLD (14.16%).
Analyst Matthew Caufield, carries an average stock price target met ratio of 22.75% that have a potential upside of 36.84% achieved within 49 days. Previously, Matthew Caufield worked at HC WAINWRIGHT.
Matthew Caufield’s has documented 214 price targets and ratings displayed on 17 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on MLYS, Mineralys Therapeutics, Common Stock at 17-Jun-2025.
Analyst best performing recommendations are on LYRA (LYRA THERAPEUTICS ).
The best stock recommendation documented was for LYRA (LYRA THERAPEUTICS ) at 3/14/2025. The price target of $2 was fulfilled within 75 days with a profit of $1.83 (1076.47%) receiving and performance score of 143.53.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$10
$6.95 (227.87%)
$10
1 months 7 days ago
(19-May-2025)
0/12 (0%)
$7.58 (313.22%)
Buy
$10
$6.95 (227.87%)
10 months 18 days ago
(08-Aug-2024)
0/1 (0%)
$5.81 (138.66%)
Buy
$8
$4.95 (162.30%)
$25
1 years 8 months 9 days ago
(17-Oct-2023)
0/10 (0%)
$6.16 (334.78%)
Hold
$14
1 years 8 months 9 days ago
(17-Oct-2023)
2/3 (66.67%)
$6.42 (84.70%)
362
Buy
3 years 6 months ago
(27-Dec-2021)
0/1 (0%)
$9.48 (75.72%)
Which stock is Matthew Caufield is most bullish on?
Which stock is Matthew Caufield is most reserved on?
What Year was the first public recommendation made by Matthew Caufield?
